ICLUSIG will be listed for the treatment of the following patients: Chronic Myeloid Leukaemia (CML) patients who are resistant or intolerant to both nilotinib and dasatinib CML patients who are expressing the T315I mutation after prior TKI therapy Philadelphia positive Acute Lymphoblastic Leukaemia (Ph+ ALL) patients who are expressing the T315I mutation after prior therapy